Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to gauge how Janux’s TRACTr and TRACIr pipelines are funded or when pivotal trial data might drop can mean sifting through hundreds of biotech-heavy pages. Janux Therapeutics insider trading Form 4 transactions, Janux Therapeutics quarterly earnings report 10-Q filing, and every 8-K that details a dosing milestone are scattered across EDGAR—hardly investor-friendly.
Stock Titan solves that problem. Our AI reads each submission the moment it posts, then delivers plain-English summaries of Janux Therapeutics SEC filings explained simply. Whether you need a quick view of cash runway from the latest Janux Therapeutics annual report 10-K simplified or want Form 4 insider transactions real-time, the platform highlights what matters and links straight to the source document.
Use cases include:
- Flagging Janux Therapeutics executive stock transactions Form 4 before clinical readouts.
- Comparing R&D spend quarter over quarter with Janux Therapeutics earnings report filing analysis.
- Monitoring 8-K material events explained—like FDA clearances or strategic partnerships.
- Reviewing Janux Therapeutics proxy statement executive compensation to see how incentives align with pipeline success.
Every filing—10-K, 10-Q, 8-K, S-3, DEF 14A—appears in one dashboard with real-time alerts, AI-powered summaries, and expert context. Still piecing together understanding Janux Therapeutics SEC documents with AI? We already parsed the technical jargon on cytokine-release risk, revenue recognition from collaborations, and liquidity projections so you can focus on decision-making.
Paradigm BioCapital and related parties disclosed ownership stakes in Janux Therapeutics common stock totaling up to 2,920,258 shares, representing 4.9% of the outstanding shares. The filing identifies four reporting persons: Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., with the Fund separately reported as holding 2,593,376 shares (4.4%). The ownership figures are stated as of the June 30, 2025 event date and are calculated using 59,175,157 shares outstanding as of May 6, 2025. The filers certify the positions were not acquired to change or influence control of the issuer.
Janus Henderson Group plc reports a passive institutional stake in Janux Therapeutics, Inc. common stock. The filing lists an aggregate beneficial ownership of 4,460,332 shares (7.5% of the class) attributed to the reporting person, while Item 4 separately identifies JHIUS as the beneficial owner of 4,379,232 shares (7.4%). The report shows shared voting and dispositive power over the shares and classifies the reporting person with reporting types IA and HC.
The filing states the shares are held in the ordinary course of business and not with the purpose of changing or influencing issuer control, and discloses that JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries acting as registered investment advisers to managed portfolios.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 2,525,000 shares of Janux Therapeutics common stock, equal to 4.27% of the company based on 59,175,157 shares outstanding as of May 6, 2025. The shares are directly held by Adage Capital Partners, L.P., and the cover data shows shared voting power and shared dispositive power for the full 2,525,000 shares and no sole voting or dispositive power.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The reporting persons list their principal business office at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts, and identify ACM as Delaware organized and Messrs. Atchinson and Gross as U.S. citizens.
FAQ
What is the current stock price of Janux Therapeutics (JANX)?
What is the market cap of Janux Therapeutics (JANX)?
